US20050069505A1 - Orally administrable composition for the photoprotection of the skin - Google Patents

Orally administrable composition for the photoprotection of the skin Download PDF

Info

Publication number
US20050069505A1
US20050069505A1 US10/505,305 US50530504A US2005069505A1 US 20050069505 A1 US20050069505 A1 US 20050069505A1 US 50530504 A US50530504 A US 50530504A US 2005069505 A1 US2005069505 A1 US 2005069505A1
Authority
US
United States
Prior art keywords
bifidobacterium
group
lactic acid
cncm
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/505,305
Other languages
English (en)
Inventor
Lionel Breton
Isabelle Bureau-Franz
Chantal Fanchon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Assigned to NESTEC S.A. reassignment NESTEC S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRETON, LIONEL, BUREAU-FRANZ, ISABELLE, FANCHON, CHANTAL
Publication of US20050069505A1 publication Critical patent/US20050069505A1/en
Priority to US11/772,704 priority Critical patent/US10688139B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria

Definitions

  • the present invention relates to orally administrable composition or pharmaceutical compositions, or cosmetical compositions, for the protection of the skin against negative effects from the environment, in particular exposure to solar radiation, which is orally administrable, and a method to improve the photoprotection of the skin.
  • the present invention aims to provide an orally administrable composition for the photoprotection of the skin which comprises a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one carotenoid or derivative, included into an orally acceptable carrier.
  • the present invention further relates to the use of a photoprotecting effective amount of at least one probiotic lactic acid bacterium or a culture supernatant thereof and at least one carotenoid, included into an orally acceptable carrier for preparing an orally administrable composition for protecting the skin against solar radiations such as ultraviolet and all related skin disorders, such as erythema, inflammation, sun burn, barrier function, photoageing, alteration of the immune system, for example.
  • solar radiations such as ultraviolet and all related skin disorders, such as erythema, inflammation, sun burn, barrier function, photoageing, alteration of the immune system, for example.
  • the invention relates to a method for improving the photoprotective function of the skin, which comprises the step of orally administering to the individual a composition comprising a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one carotenoid or derivative, in an orally acceptable carrier.
  • the combination according to the present invention has a particular beneficial effect on skin protection and coloration of the skin that helps to reduce the effects of solar radiation-related stress on skin.
  • NCC designates Nestle Culture Collection (Nestlé Research Center, Vers-chez-les-Blanc, Lausanne, Switzerland).
  • photoprotection is used to describe attempt to block or reduce the adverse clinical, histological and immunological effects of solar radiation exposure on the skin.
  • the subject compositions comprise, as the active agents therefor, combinatory immixture of at least one probiotic lactic acid bacterium or a culture supernatant thereof, and at least one carotenoid or derivative.
  • Probiotics are non-pathogenic and non-toxigenic organisms that survive passage through the stomach and small intestine. Upon continuous ingestion by the host they eventually may colonize the gut to a substantial extent thus competing with other potentially pathogenic bacteria for nutrients and/or attachment sites on the gastro-intestinal wall and reducing their numbers and reducing or preventing infections. Until now a number of different probiotic microorganisms have been found, which all are reported to exert their effect in the gut via the production of toxins, metabolic by-products, short chain fatty acids and the like.
  • composition having a synergistic photoprotective effect on the skin may be obtained by combining into an orally acceptable carrier, a probiotic microorganism and an active compound such as carotenoid.
  • the probiotic to be included into the carrier is selected from the group consisting of lactic acid bacteria, in particular Lactobacilli and/or Bifidobacteria and are more preferably Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus casei or Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum , or a mixture thereof.
  • Lactobacilli and/or Bifidobacteria are more preferably Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacill
  • the strains Lactobacillus johnsonii NCC 533 , Lactobacillus paracasei NCC 2461 , Bifidobacterium adolescentis NCC 251 and Bifidobacterium longum NCC 490 were deposited by way of an example, under the Budapest Treaty with the Institut Pasteur (28 rue du Dondel Roux, F-75024 Paris cédex 15) on 30.06.92, 12.01.99, 15.04.99 and 15.03.99, respectively and under the deposit number CNCM I-1225, CNCM I-2116, CNCM I-2168 and CNCM I-2170, respectively.
  • the strain of Bifidobacterium lactis (ATCC27536) provided by Hansen (Chr. Hansen A/S, 10-12 Boege Alle, P.O. Box 407, DK-2970 Hoersholm, Danemark) can also be used.
  • the probiotic microorganism according to the present invention may be included in a live form, dead form, semi-active or in deactivated form and fragments or fractions originating from the microorganism either live or dead e.g. as a lyophilized powder.
  • culture supernatants of the microorganisms may be included in the products, optionally in concentrated form. It may also be included in an encapsulated form.
  • the supernatant may be used as such or may be subjected to one or more purification steps prior to inclusion into the product, so as to concentrate or isolate the active ingredient (s)/metabolite (s).
  • Method and techniques for purifying compounds and detecting the activity thereof in the fractions obtained are well known to the skilled person.
  • the probiotic lactic acid bacteria may be present in the carrier in an amount of at least 10 5 cfu/g of carrier and preferably from about 10 5 to 10 15 cfu/g of orally acceptable carrier, and more preferably from 10 7 to 10 12 cfu/g of orally acceptable carrier.
  • the carotenoid may be a carotenoid with or without provitamin A activity. It may be ⁇ -carotene, ⁇ -carotene, ⁇ -carotene, lycopene, zeaxanthine and luteine, or a mixture thereof.
  • the carotenoid may be from synthetic or natural origin or contained in a natural extract. When the carotenoid is from natural origin, it is preferably obtained from plant material, in which the plant is grown in-vivo or in-vitro. Method for extracting the carotenoids is well known in the art.
  • the carotenoid may be present in the carrier in an amount of from 10-12% to 20% by weight and preferably from 0.00001 mg to 50 mg/day and more preferably from 0.001 mg to 30 mg/day.
  • a mixture of a plurality of lactic acid bacteria or carotenoids may also be used.
  • the carrier may be any food or pharmaceutical product, or a nutritional supplement for oral administration or a composition for oral administration, wherein the probiotic microorganism and the carotenoid may be included.
  • food or pharmaceuticals carriers are milk, yoghurt, curd, cheese, fermented milks, milk based fermented products, ice-creams, fermented cereal based products, milk based powders, infant formulae or tablets, liquid suspensions, dried oral supplement, wet oral supplement, dry-tube-feeding.
  • the nutritionally supplement for oral administration may be in capsules, soft capsules, tablets, pastes or pastilles, gums, or drinkable solutions or emulsions. Methods for preparing the carrier are common knowledge.
  • the composition according to the invention may further comprise bioactive molecules or yeast extracts, for example.
  • the yeast is any food-grade yeast selected from the group consisting of Ascomycotina or Deuteromycotina.
  • the yeast may be selected from the group consisting of Debaryomyces, Kluyveromyces, Saccharomyces, Yarrowia, Zygosaccharomyces, Candida and Rhodutorula , and more preferably Saccharomyces caerevisae (baker's yeast).
  • Such yeast may be used in the form of dried or lyophilized extracts. It may be present in the carrier in an amount of at least 10 5 cfu/g of orally acceptable carrier, preferably from about 10 5 to 10 15 cfu/g of orally acceptable carrier, and more preferably from 10 7 to 10 12 cfu/g of orally acceptable carrier, said amount depending on the nature and activity of the particular yeast.
  • composition according to the invention may also comprise usual excipients, in particular sweeteners, flavouring agents or preservatives.
  • composition according to the invention provides a surprising and synergistic protective and preventive effect of the skin.
  • the invention relates to a method for improving the photoprotective function of the skin, which comprises the step of orally administering to an individual a composition comprising a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one carotenoid or derivative, in an orally acceptable carrier.
  • the amount of the composition to be consumed by the individual will depend on the desirable effect. However, an amount of the composition to provide a daily amount of about 10 5 to 10 15 organisms, which organism may be alive or dead, and from 0.00001 mg to 50 mg of carotenoids, would usually are adequate.
  • composition is administered to an individual before or during the exposure to ultraviolet radiation, in particular exposure to sun.
  • ultraviolet radiation in particular exposure to sun.
  • ⁇ -carotene is provided by Roche
  • Lycopene is provided by Lycored
  • Lyophilized S. cerevissae is provided by BioSpringer
  • Latobacillus CNCM I-1225 dry mix Lactobacillus CNCM I-2116 or Bifidobacterium CNCM I-2168 dry mix are prepared so that they contain 1.10 8 to 1.10 9 organisms.
  • a photoprotective daily orally administrable composition is prepared as follows: ⁇ -carotene 4.7 mg Latobacillus CNCM I-1225 dry mix 50 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg
  • composition is administered to the individual in an amount of 2 ⁇ 500 mg daily, which provides a protective and preventive effect of the skin.
  • a photoprotective daily orally administrable composition is prepared as follows: ⁇ -carotene 4.7 mg Zeaxanthine 10 mg Latobacillus CNCM I-1225 dry mix 50 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg
  • composition is administered to the individual in an amount of 2 ⁇ 500 mg daily, which provides a protective and preventive effect of the skin.
  • a photoprotective daily orally administrable composition is prepared as follows: ⁇ -carotene 4.7 mg Lycopene 2.5 mg Bifidobacterium CNCM I-2168 dry mix 30 mg Latobacillus CNCM I-1225 dry mix 30 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg
  • composition is administered to the individual in an amount of 2 ⁇ 500 mg daily, which provides a protective and preventive effect of the skin.
  • a photoprotective daily orally administrable composition is prepared as follows: Lycopene 2.5 mg Lyophilized S. cerevissae 75 mg Latobacillus CNCM I-2116 dry mix 50 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg
  • composition is administered to the individual in an amount of 2 ⁇ 500 mg daily, which provides a protective and preventive effect of the skin.
  • a photoprotective daily orally administrable composition is prepared as follows: ⁇ -carotene 4.7 mg Lycopene 2.5 mg Lyophilized S. cerevissae 75 mg Latobacillus CNCM I-1225 dry mix 50 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg
  • a photoprotective daily orally administrable composition is prepared as follows: ⁇ -carotene 4.7 mg Lyophilized S. cerevissae 75 mg Latobacillus CNCM I-1225 dry mix 50 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg
  • composition is administered to the individual in an amount of 2 ⁇ 500 mg daily, which provides a protective and preventive effect of the skin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US10/505,305 2002-02-21 2003-02-18 Orally administrable composition for the photoprotection of the skin Abandoned US20050069505A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/772,704 US10688139B2 (en) 2002-02-21 2007-07-02 Orally administrable composition for the photoprotection of the skin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02075703 2002-02-21
EP02075703.5 2002-02-21
PCT/EP2003/001685 WO2003070203A1 (en) 2002-02-21 2003-02-18 Orally administrable composition for the photoprotection of the skin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/772,704 Division US10688139B2 (en) 2002-02-21 2007-07-02 Orally administrable composition for the photoprotection of the skin

Publications (1)

Publication Number Publication Date
US20050069505A1 true US20050069505A1 (en) 2005-03-31

Family

ID=27741186

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/505,305 Abandoned US20050069505A1 (en) 2002-02-21 2003-02-18 Orally administrable composition for the photoprotection of the skin
US11/772,704 Active 2027-09-10 US10688139B2 (en) 2002-02-21 2007-07-02 Orally administrable composition for the photoprotection of the skin

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/772,704 Active 2027-09-10 US10688139B2 (en) 2002-02-21 2007-07-02 Orally administrable composition for the photoprotection of the skin

Country Status (23)

Country Link
US (2) US20050069505A1 (zh)
EP (1) EP1478329B1 (zh)
JP (1) JP2005526038A (zh)
KR (1) KR20040096604A (zh)
CN (1) CN1301708C (zh)
AR (1) AR038594A1 (zh)
AT (1) ATE325604T1 (zh)
AU (1) AU2003232184B2 (zh)
BR (1) BR0307875B1 (zh)
CA (1) CA2477144C (zh)
DE (1) DE60305159T2 (zh)
DK (1) DK1478329T3 (zh)
ES (1) ES2263990T3 (zh)
HK (1) HK1079104A1 (zh)
MX (1) MXPA04008177A (zh)
NO (1) NO20043848L (zh)
PL (1) PL372146A1 (zh)
PT (1) PT1478329E (zh)
RU (1) RU2309760C2 (zh)
TW (1) TWI344845B (zh)
UA (1) UA77066C2 (zh)
WO (1) WO2003070203A1 (zh)
ZA (1) ZA200407551B (zh)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050238631A1 (en) * 2003-12-04 2005-10-27 Steve Burwell Methods and compositions for preventing biofilm formation, reducing existing biofilms, and for reducing populations of bacteria
US20070042005A1 (en) * 2003-03-26 2007-02-22 Michael Crothers Pharmaceutical composition comprising fungal cell or fragment thereof
US20070280999A1 (en) * 2002-02-21 2007-12-06 Nestec S.A. Orally administrable composition for the photoprotection of the skin
US20090118227A1 (en) * 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
US20090118229A1 (en) * 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
US20090118228A1 (en) * 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
US20110082218A1 (en) * 2006-06-15 2011-04-07 Karin Wertz Treatment and modulation of gene expression and skin aging
US20120064051A1 (en) * 2009-05-11 2012-03-15 Nestec S.A. Infant and young children feeding formula comprising probiotics for infants and young children
US20130004540A1 (en) * 2010-11-11 2013-01-03 O'mahony Liam Bifidobacterium strain
US20130316041A1 (en) * 2011-08-19 2013-11-28 Steven J. Maranz Use of probiotic organisms synthesizing carotenoid compounds to enhance human health and nutrition
US9439933B2 (en) * 2010-06-28 2016-09-13 Kabushiki Kaisha Yakult Honsha Skin properties improving agent for oral administration
WO2023079276A1 (en) * 2021-11-03 2023-05-11 Iiaa Limited Compositions comprising probiotic and postbiotic strains of bacteria

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106131A1 (en) * 2002-02-21 2005-05-19 Lionel Breton Photoprotective orally administrable composition for skin
US8088363B2 (en) 2002-10-28 2012-01-03 Zeavision Llc Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
FR2876029B1 (fr) * 2004-10-04 2008-11-14 Oreal Composition cosmetique et/ou dermatologique pour peaux sensibles.
MX2007004135A (es) * 2004-10-04 2007-06-15 Oreal Composicion cosmetica y/o dermatologica para pieles sensibles.
US20060269508A1 (en) 2005-03-29 2006-11-30 Trejo Amy V Means for regulating the cosmetic appearance and/or health of human keratinous tissue
WO2006110631A1 (en) 2005-04-08 2006-10-19 The Procter & Gamble Company Methods of use of orally administered probiotic bifidobacteria for human beauty benefits
AT501919B1 (de) * 2005-06-14 2008-09-15 Erber Ag Probiotischer, gesundheits- bzw. leistungsfördernder futtermittel- und/oder trinkwasserzusatz für tiere sowie seine verwendung
FR2920305B1 (fr) 2007-09-04 2010-07-30 Oreal Utilisation d'un lysat de bifidobacterium species pour le traitement de peaux sensibles.
FR2920304B1 (fr) 2007-09-04 2010-06-25 Oreal Utilisation cosmetique de lysat bifidobacterium species pour le traitement de la secheresse.
FR2942719B1 (fr) 2009-03-04 2011-08-19 Oreal Utilisation de microorganismes probiotiques pour limiter les irritations cutanees
FR2953408B1 (fr) * 2009-12-08 2013-02-08 Oreal Microorganismes probiotiques a titre d'actif pour l'eclat du teint de la peau
US20130004463A1 (en) * 2010-01-06 2013-01-03 Kabushiki Kaisha Yakult Honsha Dna damage repair promoter for oral application, and elastase activity inhibitor for oral application
EA028377B1 (ru) 2011-04-08 2017-11-30 Кр. Хансен А/С Противомикробная композиция
MY171851A (en) 2011-06-20 2019-11-04 Heinz Co Brands H J Llc Probiotic compositions and methods
WO2013130773A2 (en) 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions of microbiota and methods related thereto
US10059919B2 (en) 2012-04-09 2018-08-28 Chr. Hansen A/S Bioprotection using Lactobacillus paracasei strains
EA036321B1 (ru) 2012-04-09 2020-10-26 Кр. Хансен А/С Штамм lactobacillus paracasei chcc12777 dsm24651, обладающий противогрибковыми свойствами
CN113730442A (zh) 2014-10-31 2021-12-03 潘德勒姆治疗公司 与病症的微生物治疗和诊断有关的方法和组合物
US20160271189A1 (en) * 2015-03-18 2016-09-22 Whole Biome, Inc. Methods and compositions relating to microbial treatment and diagnosis of skin disorders
KR20180056775A (ko) 2015-10-07 2018-05-29 갈데르마 리써어치 앤드 디벨로프먼트 유산균 함유 조성물 및 아토피 피부염을 치료하기 위한 이의 용도
CA3073838A1 (en) 2017-08-30 2019-03-07 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
US11207360B2 (en) * 2017-11-28 2021-12-28 NUTRAVIS S.r.l. Composition for the treatment of dysbiosis of the intestinal microbiota
DE102018000033A1 (de) * 2018-01-03 2019-07-25 Torsten Schott Verfahren zur beschleunigten Allgemein- und Hautregeneration sowie Wundheilung

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US539773A (en) * 1895-05-21 Carburetor
US3920834A (en) * 1970-07-10 1975-11-18 Hoffmann La Roche Light-screening compositions and method
US4464362A (en) * 1980-06-27 1984-08-07 Estee Lauder Inc. Topical skin repair composition
US4646362A (en) * 1985-01-10 1987-03-03 Kimberly-Clark Corporation Disposable underpants, such as child's training pants and the like
US4806368A (en) * 1987-09-16 1989-02-21 Reddy Malireddy S Shelf life and subsequent growth of lactobacillus acidophilus, propionibacterium shermanii and leuconostoc citrovorum in dietary fiber based supplement preparation
US5192565A (en) * 1990-09-28 1993-03-09 Nestec S.A. Preservation of vegetables and fruits
US5501857A (en) * 1992-07-24 1996-03-26 Midwestern Bio-Ag Products & Services, Inc. Oral nutritional and dietary composition
US5603930A (en) * 1992-07-06 1997-02-18 Nestec S.A. Lactobacillus johnsonii CNCM I-1225
US6030650A (en) * 1996-11-22 2000-02-29 Princeton Nutrition, L.L.C. Complete nutritional milk compositions and products
US6110478A (en) * 1996-06-12 2000-08-29 Laboratoire Oenobiol Composition having tanning and photoprotective activity, and its cosmetic applications
US6156355A (en) * 1998-11-02 2000-12-05 Star-Kist Foods, Inc. Breed-specific canine food formulations
US6254886B1 (en) * 1997-12-19 2001-07-03 Merck Patent Gmbh Multilayer tablet
US20010006671A1 (en) * 2000-01-03 2001-07-05 Louis P. Goodman Gel system for oral and topical administration of water insoluble and/or water intolerant drugs and supplements
US20030059501A1 (en) * 2000-05-03 2003-03-27 Vincent Rivier Confectionery product containing functional ingredients
US20040013732A1 (en) * 2001-09-25 2004-01-22 Michael Farber Starch-based delivery system for creatine
US20050158291A1 (en) * 2002-02-21 2005-07-21 Lionel Breton Pet food composition for skin photoprotection
US7037708B1 (en) * 1998-04-30 2006-05-02 Basf Aktiengesellschaft Dried microorganism cultures and method for producing same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223491A (en) * 1989-11-09 1993-06-29 Donzis Byron A Method for revitalizing skin by applying topically water insoluble glucan
FR2698268B1 (fr) 1992-11-24 1995-01-20 Oreal Composition photoprotectrice administrée par voie orale.
JP3347381B2 (ja) * 1993-01-27 2002-11-20 協和醗酵工業株式会社 ペットフード
FR2718752B1 (fr) 1994-04-15 1996-07-12 World Trust Investment Sa Préparations à base de lactosérum fermenté et leurs utilisations.
FR2725896B1 (fr) 1994-10-19 1996-11-29 Sederma Sa Nouvelles compositions cosmetiques ou dermopharmaceutiques
IT1274654B (it) 1995-02-28 1997-07-18 Newpharma Srl Associazioni di fermenti lattici e lisati di saccaromiceti loro uso terapeutico e composizioni che le contengono
EP1067945B1 (en) * 1998-04-01 2006-01-04 Ganeden Biotech, Inc. Methods for reducing cholesterol using bacillus coagulans spores, systems and compositions
NL1010770C2 (nl) 1998-12-09 2000-06-13 Nutricia Nv Preparaat dat oligosacchariden en probiotica bevat.
EP1020123A1 (en) * 1999-01-18 2000-07-19 Sitia-Yomo S.p.A. Beverages containing live lactic bacteria
SE523771C2 (sv) * 1999-05-21 2004-05-18 Probi Ab Sportdryck innehållande mikronäringsämnen i kombination med levande laktobaciller
JP2001000142A (ja) * 1999-06-23 2001-01-09 Artnature Co Ltd 育毛および発毛用栄養補助食品
ATE512594T1 (de) * 1999-09-09 2011-07-15 Nestle Sa Verbesserung des zustandes älterer haustiere
EP1110555A1 (fr) * 1999-12-22 2001-06-27 Societe Des Produits Nestle S.A. Agent anti-adhesion de la flore pathogene de la peau
IL151596A0 (en) * 2000-03-24 2003-04-10 Nestle Sa Use of lactic acid bacterium for the treatment of peritonitis
CN100553646C (zh) * 2000-10-06 2009-10-28 雀巢产品股份有限公司 用乳酸菌微生态制剂调节皮肤免疫系统
US6864231B2 (en) 2001-01-09 2005-03-08 Pharmachem Laboratories, Inc. Glycoprotein matrix compositions and methods related thereto
DE60305159T2 (de) * 2002-02-21 2007-03-15 Société des Produits Nestlé S.A. Oral verabreichbare zusammensetzung zum schutz der haut vor licht
US20050106131A1 (en) * 2002-02-21 2005-05-19 Lionel Breton Photoprotective orally administrable composition for skin

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US539773A (en) * 1895-05-21 Carburetor
US3920834A (en) * 1970-07-10 1975-11-18 Hoffmann La Roche Light-screening compositions and method
US4464362A (en) * 1980-06-27 1984-08-07 Estee Lauder Inc. Topical skin repair composition
US4646362A (en) * 1985-01-10 1987-03-03 Kimberly-Clark Corporation Disposable underpants, such as child's training pants and the like
US4806368A (en) * 1987-09-16 1989-02-21 Reddy Malireddy S Shelf life and subsequent growth of lactobacillus acidophilus, propionibacterium shermanii and leuconostoc citrovorum in dietary fiber based supplement preparation
US5192565A (en) * 1990-09-28 1993-03-09 Nestec S.A. Preservation of vegetables and fruits
US5603930A (en) * 1992-07-06 1997-02-18 Nestec S.A. Lactobacillus johnsonii CNCM I-1225
US5501857A (en) * 1992-07-24 1996-03-26 Midwestern Bio-Ag Products & Services, Inc. Oral nutritional and dietary composition
US6110478A (en) * 1996-06-12 2000-08-29 Laboratoire Oenobiol Composition having tanning and photoprotective activity, and its cosmetic applications
US6030650A (en) * 1996-11-22 2000-02-29 Princeton Nutrition, L.L.C. Complete nutritional milk compositions and products
US6254886B1 (en) * 1997-12-19 2001-07-03 Merck Patent Gmbh Multilayer tablet
US7037708B1 (en) * 1998-04-30 2006-05-02 Basf Aktiengesellschaft Dried microorganism cultures and method for producing same
US6156355A (en) * 1998-11-02 2000-12-05 Star-Kist Foods, Inc. Breed-specific canine food formulations
US20010006671A1 (en) * 2000-01-03 2001-07-05 Louis P. Goodman Gel system for oral and topical administration of water insoluble and/or water intolerant drugs and supplements
US20030059501A1 (en) * 2000-05-03 2003-03-27 Vincent Rivier Confectionery product containing functional ingredients
US20040013732A1 (en) * 2001-09-25 2004-01-22 Michael Farber Starch-based delivery system for creatine
US20050158291A1 (en) * 2002-02-21 2005-07-21 Lionel Breton Pet food composition for skin photoprotection

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070280999A1 (en) * 2002-02-21 2007-12-06 Nestec S.A. Orally administrable composition for the photoprotection of the skin
US20070042005A1 (en) * 2003-03-26 2007-02-22 Michael Crothers Pharmaceutical composition comprising fungal cell or fragment thereof
US20050238631A1 (en) * 2003-12-04 2005-10-27 Steve Burwell Methods and compositions for preventing biofilm formation, reducing existing biofilms, and for reducing populations of bacteria
US20110082218A1 (en) * 2006-06-15 2011-04-07 Karin Wertz Treatment and modulation of gene expression and skin aging
US20090118227A1 (en) * 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
US20090118228A1 (en) * 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
US20090118229A1 (en) * 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
US9072314B2 (en) 2007-11-07 2015-07-07 Mead Johnson Nutrition Company Carotenoid-containing compositions and methods
US20120064051A1 (en) * 2009-05-11 2012-03-15 Nestec S.A. Infant and young children feeding formula comprising probiotics for infants and young children
US9439933B2 (en) * 2010-06-28 2016-09-13 Kabushiki Kaisha Yakult Honsha Skin properties improving agent for oral administration
US20130004540A1 (en) * 2010-11-11 2013-01-03 O'mahony Liam Bifidobacterium strain
US9259019B2 (en) * 2010-11-11 2016-02-16 Mars, Incorporated Bifidobacteriumstrain
US20130316041A1 (en) * 2011-08-19 2013-11-28 Steven J. Maranz Use of probiotic organisms synthesizing carotenoid compounds to enhance human health and nutrition
US9113653B2 (en) * 2011-08-19 2015-08-25 Steven J Maranz Methods of administering probiotic organisms that synthesize carotenoid compounds in situ to enhance human health and nutrition
WO2023079276A1 (en) * 2021-11-03 2023-05-11 Iiaa Limited Compositions comprising probiotic and postbiotic strains of bacteria

Also Published As

Publication number Publication date
CA2477144C (en) 2011-06-14
AR038594A1 (es) 2005-01-19
ES2263990T3 (es) 2006-12-16
NO20043848L (no) 2004-09-14
CN1301708C (zh) 2007-02-28
BR0307875B1 (pt) 2014-12-23
TWI344845B (en) 2011-07-11
UA77066C2 (en) 2006-10-16
US20070280999A1 (en) 2007-12-06
EP1478329B1 (en) 2006-05-10
DE60305159T2 (de) 2007-03-15
US10688139B2 (en) 2020-06-23
MXPA04008177A (es) 2005-06-08
RU2004127986A (ru) 2005-05-10
ZA200407551B (en) 2005-10-12
EP1478329A1 (en) 2004-11-24
HK1079104A1 (en) 2006-03-31
KR20040096604A (ko) 2004-11-16
CA2477144A1 (en) 2003-08-28
TW200307555A (en) 2003-12-16
CN1635865A (zh) 2005-07-06
RU2309760C2 (ru) 2007-11-10
PL372146A1 (en) 2005-07-11
WO2003070203A1 (en) 2003-08-28
BR0307875A (pt) 2004-12-28
JP2005526038A (ja) 2005-09-02
PT1478329E (pt) 2006-09-29
DK1478329T3 (da) 2006-08-28
AU2003232184B2 (en) 2008-11-13
DE60305159D1 (de) 2006-06-14
AU2003232184A1 (en) 2003-09-09
ATE325604T1 (de) 2006-06-15

Similar Documents

Publication Publication Date Title
US10688139B2 (en) Orally administrable composition for the photoprotection of the skin
EP1490077B1 (en) A photoprotective orally administrable composition for skin
US8377679B2 (en) Use of probiotic lactic acid bacteria for balancing the skin's immune system
AU2003210311C1 (en) Pet food composition for skin photoprotection
AU2003210310B2 (en) A photoprotective orally administrable composition for skin

Legal Events

Date Code Title Description
AS Assignment

Owner name: NESTEC S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRETON, LIONEL;BUREAU-FRANZ, ISABELLE;FANCHON, CHANTAL;REEL/FRAME:015297/0096

Effective date: 20040823

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION